-
公开(公告)号：US20130084294A1
公开(公告)日：2013-04-04
申请号：US13603154
申请日：2012-09-04
IPC分类号： A61K39/395
CPC分类号： C07K16/2896 , A61K38/13 , A61K39/39541 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/54 , C07K16/2803 , C07K16/2887 , C07K2317/73 , C07K2317/732 , C07K2317/77
摘要： The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies and autoimmune diseases and disorders, using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.
摘要翻译： 本发明涉及使用结合人CD19抗原的治疗性抗体来治疗人受试者中B细胞疾病和病症的免疫治疗组合物和方法，例如但不限于B细胞恶性肿瘤和自身免疫疾病和病症， 优选介导人ADCC。 本发明涉及包含IgG1或IgG3人同种型的人或人源化抗CD19抗体的药物组合物。 本发明涉及药物组合物，其包含优选介导人ADCC的IgG2或IgG4人同种型人或人源化抗CD19抗体。 本发明还涉及包含介导人ADCC的IgG1，IgG2，IgG3或IgG4同种型的嵌合抗CD19抗体的药物组合物。 在优选的实施方案中，本发明涉及包含单克隆人，人源化或嵌合抗-CD19抗体的药物组合物。
-
公开(公告)号：US20110104150A1
公开(公告)日：2011-05-05
申请号：US12885341
申请日：2010-09-17
IPC分类号： A61K39/395
CPC分类号： C07K16/2896 , A61K38/13 , A61K39/39541 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/54 , C07K16/2803 , C07K16/2887 , C07K2317/73 , C07K2317/732 , C07K2317/77
摘要： The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies and autoimmune diseases and disorders, using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.
摘要翻译： 本发明涉及使用结合人CD19抗原的治疗性抗体来治疗人受试者中B细胞疾病和病症的免疫治疗组合物和方法，例如但不限于B细胞恶性肿瘤和自身免疫疾病和病症， 优选介导人ADCC。 本发明涉及包含IgG1或IgG3人同种型的人或人源化抗CD19抗体的药物组合物。 本发明涉及药物组合物，其包含优选介导人ADCC的IgG2或IgG4人同种型人或人源化抗CD19抗体。 本发明还涉及包含介导人ADCC的IgG1，IgG2，IgG3或IgG4同种型的嵌合抗CD19抗体的药物组合物。 在优选的实施方案中，本发明涉及包含单克隆人，人源化或嵌合抗-CD19抗体的药物组合物。
-
公开(公告)号：US20090285808A1
公开(公告)日：2009-11-19
申请号：US12401310
申请日：2009-03-10
IPC分类号： A61K39/395
CPC分类号： C07K16/2803 , A61K2039/505 , A61K2039/54 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/77
摘要： The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies, using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.
摘要翻译： 本发明涉及使用结合人CD19抗原并优选介导人ADCC的治疗性抗体来治疗人受试者中B细胞疾病和障碍的免疫治疗组合物和方法，所述B细胞疾病和病症例如但不限于B细胞恶性肿瘤。 本发明涉及包含IgG1或IgG3人同种型的人或人源化抗CD19抗体的药物组合物。 本发明涉及药物组合物，其包含优选介导人ADCC的IgG2或IgG4人同种型人或人源化抗CD19抗体。 本发明还涉及包含介导人ADCC的IgG1，IgG2，IgG3或IgG4同种型的嵌合抗CD19抗体的药物组合物。 在优选的实施方案中，本发明涉及包含单克隆人，人源化或嵌合抗-CD19抗体的药物组合物。
-
公开(公告)号：US20100158901A1
公开(公告)日：2010-06-24
申请号：US12325426
申请日：2008-12-01
IPC分类号： A61K39/395 , A61P37/00
CPC分类号： C07K16/2887 , A61K2039/505 , A61K2039/507 , C07K16/2803 , C07K16/2896 , C07K2317/24 , C07K2317/52 , C07K2317/56 , C07K2317/77
摘要： The invention relates to immunotherapeutic compositions and methods for the treatment of autoimmune diseases and disorders in human subjects using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.
摘要翻译： 本发明涉及使用结合人CD19抗原并优选介导人ADCC的治疗性抗体治疗人受试者自身免疫性疾病和病症的免疫治疗组合物和方法。 本发明涉及包含IgG1或IgG3人同种型的人或人源化抗CD19抗体的药物组合物。 本发明涉及药物组合物，其包含优选介导人ADCC的IgG2或IgG4人同种型人或人源化抗CD19抗体。 本发明还涉及包含介导人ADCC的IgG1，IgG2，IgG3或IgG4同种型的嵌合抗CD19抗体的药物组合物。 在优选的实施方案中，本发明涉及包含单克隆人，人源化或嵌合抗-CD19抗体的药物组合物。
-
公开(公告)号：US08444973B2
公开(公告)日：2013-05-21
申请号：US12885341
申请日：2010-09-17
IPC分类号： A61K39/395
CPC分类号： C07K16/2896 , A61K38/13 , A61K39/39541 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/54 , C07K16/2803 , C07K16/2887 , C07K2317/73 , C07K2317/732 , C07K2317/77
摘要： The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies and autoimmune diseases and disorders, using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.
摘要翻译： 本发明涉及使用结合人CD19抗原的治疗性抗体来治疗人受试者中B细胞疾病和病症的免疫治疗组合物和方法，所述方法例如但不限于B细胞恶性肿瘤和自身免疫性疾病和病症， 优选介导人ADCC。 本发明涉及包含IgG1或IgG3人同种型的人或人源化抗CD19抗体的药物组合物。 本发明涉及药物组合物，其包含优选介导人ADCC的IgG2或IgG4人同种型人或人源化抗CD19抗体。 本发明还涉及包含介导人ADCC的IgG1，IgG2，IgG3或IgG4同种型的嵌合抗CD19抗体的药物组合物。 在优选的实施方案中，本发明涉及包含单克隆人，人源化或嵌合抗-CD19抗体的药物组合物。
-
公开(公告)号：US20060263357A1
公开(公告)日：2006-11-23
申请号：US11429545
申请日：2006-05-05
申请人： Thomas Tedder , Yasuhito Hamaguchi , Hanne Gron , Norihito Yazawa
发明人： Thomas Tedder , Yasuhito Hamaguchi , Hanne Gron , Norihito Yazawa
IPC分类号： A61K39/395
CPC分类号： C07K16/2887 , A61K2039/505 , A61K2039/507 , C07K16/2803 , C07K16/2896 , C07K2317/24 , C07K2317/52 , C07K2317/56 , C07K2317/77
摘要： The invention relates to immunotherapeutic compositions and methods for the treatment of autoimmune diseases and disorders in human subjects using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.
摘要翻译： 本发明涉及使用结合人CD19抗原并优选介导人ADCC的治疗性抗体治疗人受试者自身免疫性疾病和病症的免疫治疗组合物和方法。 本发明涉及包含IgG1或IgG3人同种型的人或人源化抗CD19抗体的药物组合物。 本发明涉及药物组合物，其包含优选介导人ADCC的IgG2或IgG4人同种型人或人源化抗CD19抗体。 本发明还涉及包含介导人ADCC的IgG1，IgG2，IgG3或IgG4同种型的嵌合抗CD19抗体的药物组合物。 在优选的实施方案中，本发明涉及包含单克隆人，人源化或嵌合抗-CD19抗体的药物组合物。
-
公开(公告)号：US20060233791A1
公开(公告)日：2006-10-19
申请号：US11355905
申请日：2006-02-15
申请人： Thomas Tedder , Yasuhito Hamaguchi , Hanne Gron , Norihito Yazawa
发明人： Thomas Tedder , Yasuhito Hamaguchi , Hanne Gron , Norihito Yazawa
IPC分类号： A61K39/395
CPC分类号： C07K16/2803 , A61K2039/505 , A61K2039/54 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/77
摘要： The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies, using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.
摘要翻译： 本发明涉及使用结合人CD19抗原并优选介导人ADCC的治疗性抗体来治疗人受试者中B细胞疾病和障碍的免疫治疗组合物和方法，所述B细胞疾病和病症例如但不限于B细胞恶性肿瘤。 本发明涉及包含IgG1或IgG3人同种型的人或人源化抗CD19抗体的药物组合物。 本发明涉及药物组合物，其包含优选介导人ADCC的IgG2或IgG4人同种型人或人源化抗CD19抗体。 本发明还涉及包含介导人ADCC的IgG1，IgG2，IgG3或IgG4同种型的嵌合抗CD19抗体的药物组合物。 在优选的实施方案中，本发明涉及包含单克隆人，人源化或嵌合抗-CD19抗体的药物组合物。
-
公开(公告)号：US20110117167A1
公开(公告)日：2011-05-19
申请号：US12949104
申请日：2010-11-18
申请人： Isaac Gilliam Sanford , Michelle Steffen Jansen , Paul Theodore Hamilton , Jonathan Allen Hodges , Shrikumar Ambujakshan Nair , Yuchen Chen , Martyn Kerry Darby , Hanne Gron , Ganesan Sathya
发明人： Isaac Gilliam Sanford , Michelle Steffen Jansen , Paul Theodore Hamilton , Jonathan Allen Hodges , Shrikumar Ambujakshan Nair , Yuchen Chen , Martyn Kerry Darby , Hanne Gron , Ganesan Sathya
IPC分类号： A61K9/00 , C07K14/00 , C07K7/08 , C07K14/78 , C12N5/071 , C12N5/078 , A61K35/12 , A61K35/32 , A61K35/28 , A61K35/14 , A61K35/16 , A61K35/48 , A61K35/50 , C07K19/00 , A61K38/16 , A61K38/10 , A61K38/39 , A61P17/02 , A61P19/04 , A61P21/00 , A61P19/00 , A61P9/00 , C07K9/00 , C08G63/91 , A61K38/14 , A61K31/765 , C12N5/077
CPC分类号： A61K47/48992 , A61K9/0024 , A61K38/10 , A61K47/02 , A61K47/42 , A61K47/64 , A61K47/6957 , A61L27/425 , A61L27/427 , A61L27/54 , A61L27/58 , A61L2300/414 , A61L2430/02
摘要： Compositions and methods for tissue repair are provided including cell binding peptides and growth factor binding peptides. The cell binding peptides bind to one or more of stem cells, fibroblasts, or endothelial cells. The growth factor binding peptides include platelet derived growth factor (PDGF) binding peptides and growth differentiation factor (GDF) binding peptides. The tissue for repair includes tendon, muscle, connective tissue, ligament, cardiac tissue, vascular tissue, or dermis. Implantable devices for tissue repair are provided to which the cell and growth factor binding peptides are attached, such as acellular extracellular matrix having attached binding peptide.
-
公开(公告)号：US08779089B2
公开(公告)日：2014-07-15
申请号：US12949104
申请日：2010-11-18
申请人： Isaac Gilliam Sanford , Michelle Steffen Jansen , Paul Theodore Hamilton , Jonathan Allen Hodges , Shrikumar Ambujakshan Nair , Yuchen Chen , Martyn Kerry Darby , Hanne Gron , Ganesan Sathya
发明人： Isaac Gilliam Sanford , Michelle Steffen Jansen , Paul Theodore Hamilton , Jonathan Allen Hodges , Shrikumar Ambujakshan Nair , Yuchen Chen , Martyn Kerry Darby , Hanne Gron , Ganesan Sathya
IPC分类号： A61K38/10 , C07K17/00 , C07K17/12 , C07K7/08 , C07K17/08 , C07K17/10 , A61K47/48 , A61K47/02 , A61K9/00 , A61L27/54 , A61L27/58 , A61K47/42 , A61L27/42
CPC分类号： A61K47/48992 , A61K9/0024 , A61K38/10 , A61K47/02 , A61K47/42 , A61K47/64 , A61K47/6957 , A61L27/425 , A61L27/427 , A61L27/54 , A61L27/58 , A61L2300/414 , A61L2430/02
摘要： Compositions and methods for tissue repair are provided including cell binding peptides and growth factor binding peptides. The cell binding peptides bind to one or more of stem cells, fibroblasts, or endothelial cells. The growth factor binding peptides include platelet derived growth factor (PDGF) binding peptides and growth differentiation factor (GDF) binding peptides. The tissue for repair includes tendon, muscle, connective tissue, ligament, cardiac tissue, vascular tissue, or dermis. Implantable devices for tissue repair are provided to which the cell and growth factor binding peptides are attached, such as acellular extracellular matrix having attached binding peptide.
-
公开(公告)号：US20110117168A1
公开(公告)日：2011-05-19
申请号：US12949149
申请日：2010-11-18
申请人： Ganesan Sathya , Michelle Steffen Jansen , Paul Theodore Hamilton , Jonathan Allen Hodges , Shrikumar Ambujakshan Nair , Hanne Gron
发明人： Ganesan Sathya , Michelle Steffen Jansen , Paul Theodore Hamilton , Jonathan Allen Hodges , Shrikumar Ambujakshan Nair , Hanne Gron
IPC分类号： A61K9/00 , C07K7/08 , C07K7/06 , C07K19/00 , C07K9/00 , C08G63/91 , A61K38/39 , A61K38/17 , A61K38/02 , A61K31/785 , A61F2/10 , A61F2/08 , A61F2/12 , A61P43/00 , A61P9/00 , A61P17/00 , A61P19/04
CPC分类号： A61K47/64 , A61K9/0024 , A61K38/10 , A61K47/02 , A61K47/42 , A61K47/6957 , A61L27/425 , A61L27/427 , A61L27/54 , A61L27/58 , A61L2300/414 , A61L2430/02
摘要： Compositions and methods for tissue repair are provided including cell binding peptides and growth factor binding peptides. The cell binding peptides bind to one or more of stem cells, fibroblasts, or endothelial cells. The growth factor binding peptides include platelet derived growth factor (PDGF) binding peptides and growth differentiation factor (GDF) binding peptides. The tissue for repair includes tendon, muscle, connective tissue, ligament, cardiac tissue, vascular tissue, or dermis. Implantable devices for tissue repair are provided to which the cell and growth factor binding peptides are attached, such as acellular extracellular matrix having attached binding peptide.
-
-
-
-
-
-
-
-
-
搜索结果
17 条记录 (耗时 0.045 秒)
